Shandong Realcan Pharmaceutical Co Ltd (002589) — Working Capital to Net Assets Ratio
Shandong Realcan Pharmaceutical Co Ltd (002589) has a Working Capital to Net Assets ratio of 17.4% as of March 2026. Working capital of CN¥948.80 Million (current assets of CN¥10.60 Billion minus current liabilities of CN¥9.66 Billion) is measured against net assets of CN¥5.44 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Shandong Realcan Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shandong Realcan Pharmaceutical Co Ltd Working Capital to Net Assets (2008–2025)
This chart shows how Shandong Realcan Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the ratio stands at 17.4%, reflecting working capital of CN¥948.80 Million against net assets of CN¥5.44 Billion CNY. See Shandong Realcan Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 002589 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 14.6% | CN¥791.18 Million | CN¥5.42 Billion | CN¥9.45 Billion | CN¥8.66 Billion | ▼ -5.6 pp |
| 2024 | 20.2% | CN¥1.15 Billion | CN¥5.69 Billion | CN¥11.08 Billion | CN¥9.93 Billion | ▲ +6.4 pp |
| 2023 | 13.8% | CN¥777.98 Million | CN¥5.64 Billion | CN¥11.54 Billion | CN¥10.76 Billion | ▲ +7.7 pp |
| 2022 | 6.1% | CN¥351.12 Million | CN¥5.75 Billion | CN¥12.82 Billion | CN¥12.47 Billion | ▼ -36.9 pp |
| 2021 | 43.0% | CN¥4.16 Billion | CN¥9.69 Billion | CN¥20.67 Billion | CN¥16.51 Billion | ▼ -12.2 pp |
| 2020 | 55.1% | CN¥5.32 Billion | CN¥9.64 Billion | CN¥26.49 Billion | CN¥21.18 Billion | ▼ -14.1 pp |
| 2019 | 69.2% | CN¥7.10 Billion | CN¥10.25 Billion | CN¥27.76 Billion | CN¥20.66 Billion | ▲ +3.9 pp |
| 2018 | 65.3% | CN¥7.39 Billion | CN¥11.31 Billion | CN¥28.66 Billion | CN¥21.27 Billion | ▲ +8.9 pp |
| 2017 | 56.4% | CN¥5.46 Billion | CN¥9.67 Billion | CN¥21.08 Billion | CN¥15.62 Billion | ▼ -6.1 pp |
| 2016 | 62.6% | CN¥4.70 Billion | CN¥7.50 Billion | CN¥12.85 Billion | CN¥8.15 Billion | ▲ +4.0 pp |
| 2015 | 58.6% | CN¥2.00 Billion | CN¥3.40 Billion | CN¥7.45 Billion | CN¥5.46 Billion | ▼ -6.9 pp |
| 2014 | 65.5% | CN¥1.20 Billion | CN¥1.83 Billion | CN¥5.05 Billion | CN¥3.85 Billion | ▼ -6.4 pp |
| 2013 | 71.9% | CN¥1.19 Billion | CN¥1.65 Billion | CN¥3.99 Billion | CN¥2.80 Billion | ▼ -2.8 pp |
| 2012 | 74.7% | CN¥684.22 Million | CN¥916.39 Million | CN¥2.89 Billion | CN¥2.20 Billion | ▼ -10.7 pp |
| 2011 | 85.4% | CN¥697.85 Million | CN¥817.11 Million | CN¥2.10 Billion | CN¥1.40 Billion | ▲ +17.1 pp |
| 2010 | 68.4% | CN¥202.35 Million | CN¥296.03 Million | CN¥1.39 Billion | CN¥1.18 Billion | ▼ -4.0 pp |
| 2009 | 72.3% | CN¥169.39 Million | CN¥234.18 Million | CN¥975.17 Million | CN¥805.78 Million | ▲ +22.5 pp |
| 2008 | 49.8% | CN¥55.71 Million | CN¥111.89 Million | CN¥659.35 Million | CN¥603.64 Million | — |